Profile data is unavailable for this security.
About the company
Raia Drogasil SA is a Brazil-based company engaged in retail sales of medications, specialty medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. The Company’s sales are carried out by over 860 stores, located in the states of Sao Paulo, Minas Gerais, Rio de Janeiro, Parana, Goias, Espirito Santo, Santa Catarina, Rio Grande do Sul, Bahia, Mato Grosso and Mato Grosso do Sul and in the Distrito Federal. The Company operates through a range of subsidiaries, such as Raia SA and 4-Bio Medicamentos SA.
- Revenue in BRL (TTM)37.70bn
- Net income in BRL1.11bn
- Incorporated1935
- Employees62.40k
- LocationRaia Drogasil S/AAv. Corifeu de Azevedo Marques3.097, ButantaSAO PAULO 05.339-900BrazilBRA
- Phone+55 1 137695678
- Fax+55 1 137695687
- Websitehttps://rdsaude.com.br/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sendas Distribuidora SA | 72.08bn | 636.00m | 9.38bn | 80.00k | 14.83 | 1.88 | 4.18 | 0.1302 | 0.4679 | 0.4679 | 53.11 | 3.69 | 1.69 | 8.36 | 49.59 | 900,962.50 | 1.49 | -- | 2.50 | -- | 16.48 | -- | 0.8824 | -- | 0.4257 | 1.27 | 0.8386 | -- | 21.98 | -- | -41.80 | -- | -- | -- |
Atacadao SA | 113.95bn | 25.00m | 13.31bn | 95.67k | 539.78 | 0.6707 | 6.38 | 0.1168 | 0.0117 | 0.0117 | 54.06 | 9.41 | 1.29 | 7.08 | 30.17 | -- | 0.2761 | 2.85 | 0.5496 | 5.80 | 18.48 | 19.34 | 0.2133 | 2.11 | 0.6357 | 2.45 | 0.5075 | 46.71 | 6.77 | 15.15 | -145.72 | -- | 14.43 | -15.92 |
Grupo Mateus SA | 30.90bn | 1.32bn | 15.86bn | 29.67k | 11.75 | 1.67 | 8.27 | 0.5131 | 0.5974 | 0.5974 | 13.98 | 4.20 | 1.88 | 4.40 | 9.69 | -- | 8.10 | 9.10 | 10.98 | 11.61 | 22.34 | 22.85 | 4.32 | 4.87 | 0.9523 | 9.64 | 0.2898 | -- | 22.99 | 31.22 | 16.00 | 32.54 | 49.67 | -- |
Raia Drogasil S/A | 37.70bn | 1.11bn | 43.59bn | 62.40k | 38.02 | 6.90 | 14.76 | 1.16 | 0.6673 | 0.6673 | 22.54 | 3.67 | 1.82 | 3.51 | 12.44 | 653,501.50 | 5.51 | 5.78 | 9.39 | 9.25 | 29.83 | 29.92 | 3.02 | 3.33 | 0.5117 | 3.28 | 0.549 | 44.25 | 16.88 | 18.08 | 5.91 | 15.99 | 13.16 | 20.02 |
Data as of Nov 22 2024. Currency figures normalised to Raia Drogasil S/A's reporting currency: Brazilian Real BRL
Holder | Shares | % Held |
---|---|---|
Schroder Investment Management Ltd.as of 30 Sep 2024 | 57.94m | 3.37% |
RBC Global Asset Management (UK) Ltd.as of 30 Sep 2024 | 52.58m | 3.06% |
The Vanguard Group, Inc.as of 06 Nov 2024 | 42.51m | 2.47% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 38.44m | 2.24% |
Invesco Advisers, Inc.as of 14 Nov 2024 | 34.75m | 2.02% |
Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 32.18m | 1.87% |
Wasatch Advisors LPas of 30 Sep 2024 | 24.53m | 1.43% |
JPMorgan Asset Management (UK) Ltd.as of 08 Nov 2024 | 24.48m | 1.43% |
JPMorgan Investment Management, Inc.as of 07 Nov 2024 | 20.63m | 1.20% |
Sands Capital Management LLCas of 31 Oct 2024 | 17.19m | 1.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.